Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to BNF eNews
BNF BNF for Children Medicines Complete
July 2018 Share this issue Facebook LinkedIn Twitter
 
I Welcome
Welcome to the July BNF eNewsletter.
Two new drug monographs have been added to the BNF, including gemtuzumab ozogamicin and palivizumab and five to the BNFC, including golimumab, tiotropium, trospium chloride and valganciclovir.

This issue includes dose changes for amitriptyline, ganciclovir, ivabradine, sildenafil, and tadalafil. We have included MHRA advice on Braltus® (tiotropium) and the risk of inhalation of the capsule if placed in the mouthpiece of the inhaler, and Tivicay® (dolutegravir), Triumeq® (dolutegravir, abacavir, lamivudine), Juluca® (dolutegravir, rilpivirine) and reports of neural tube defects in infants born to women exposed to dolutegravir at the time of conception. You will also find NICE technology appraisals for atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer, avelumab for treating metastatic Merkel cell carcinoma, pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy.

Also check out our latest BNF case study on Giant Cell Arteritis, looking at treatment options and monitoring.
Kind regards,
BNF Team
I In this issue
Thank you from MedicinesComplete! More >  
Significant changes More >  
News More >  
How to purchase BNF More >  
Drug safety update More >  
Feedback More >  
I Thank you from MedicinesComplete!
The new MedicinesComplete has been up and running for a few weeks and we would like to say a big thank you to everyone and we hope you are enjoying it.

Don't forget, to help you navigate your way around we've created a user guide so you can get to grips with all the new features and benefits. There is also a helpful FAQ's section on the site to help you with any general queries and our support team is available to help should you have any questions about the new platform.

Once you've had the chance to experience MedicinesComplete for yourself we would really appreciate your feedback! What do you think about the new platform? What works well, and what could be improved? We'd also appreciate it if you could provide us with a testimonial. Look out for our short feedback survey coming soon!

Continue sharing any general or specific feedback on your MedicinesComplete experience via the home page. Log in and then click on the blue Feedback tab on the right hand side of the page.

Remember to forward this email to your colleagues so they are also aware of the latest updates to MedicinesComplete.

Best wishes,
The MedicinesComplete team
I Significant changes
This month's changes to the clinical content of these publications are described in three parts:

BNF and BNFC update should be read by all users
BNF update should be read by all users of the BNF
BNFC update should be read by all users of the BNF for Children
BNF 72 - BNFC 2016-2017
BNF BNF for Children Update
Gemtuzumab ozogamicin: new drug monograph
For further information, see gemtuzumab ozogamicin.
Tivicay® (dolutegravir), Triumeq® (dolutegravir, abacavir, lamivudine), Juluca® (dolutegravir, rilpivirine): neural tube defects reported in infants born to women exposed to dolutegravir at the time of conception (MHRA advice)
For further information, see dolutegravir.
Daclizumab: marketing authorisation withdrawn for safety reasons
Dose changes
Ganciclovir
For further information, see ganciclovir.
Vancomycin
For further information, see vancomycin.
BNF for Children Update
Golimumab: new drug monograph
For further information, see golimumab.
Tiotropium: new drug monograph
For further information, see tiotropium.
Trospium chloride: new drug monograph
For further information, see trospium chloride.
Valganciclovir: new drug monograph
For further information, see valganciclovir.
Dose changes
Amitriptyline [dose for depression deleted]
For further information, see amitriptyline hydrochloride.
Other changes
To review other changes in BNF for Children, click on changes.
BNF Update
Palivizumab: new drug monograph
For further information, see palivizumab.
Braltus® (tiotropium): risk of inhalation of capsule if placed in the mouthpiece of the inhaler (MHRA advice)
For further information, see tiotropium.
Dose changes
Amitriptyline [doses for depression, neuropathic pain, and migraine prophylaxis]
For further information, see amitriptyline hydrochloride.
Sildenafil [digital ulcers - associated with systemic sclerosis][unlicensed]
For further information, see sildenafil.
Tadalafil [clarification of dosing for intermittent use in erectile dysfunction and dosing in hepatic and renal impairment]
For further information, see tadalafil.
NICE technology appraisal update:
NICE technology appraisals that have been added to the BNF this month include:
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Avelumab for treating metastatic Merkel cell carcinoma
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Other changes
To review other changes in BNF, click on changes.
I News
BNF Case study: Treatment of Giant Cell Arteritis
Check out the latest BNF case study on giant cell arteritis, looking at treatment options and monitoring.
Reminder - help from CPPE with BNF 75
An interactive PDF e-learning programme from the Centre for Pharmacy Postgraduate Education (CPPE) will help you familiarise yourself with recommendations in BNF 75. It comprises 10 practical case studies that help you keep up to date with recent changes in the BNF, and can be accessed here.
BNF 74
I How to purchase BNF
Purchase Print copies
Purchase print copies
To order the March 2018 edition, visit the Pharmaceutical Press website.
More
Purchase a print subscription
Purchase a print subscription and save money
A print subscription is the best way to ensure access to the latest copy of BNF as soon as it publishes.
More
BNF online
BNF online
Outside the UK, content is available via a subscription to MedicinesComplete.
Email us
BNF eBook
BNF eBook
BNF is also available as a PDF eBook.
More
Drug Safety Update
Drug Safety Update is a monthly newsletter from
the MHRA and Commission on Human Medicine.
Please follow this link to review this month's Drug Safety Update.
I Feedback on our eNewsletter
Please let us know if there are any issues that you'd like us to address in our eNewsletters. We welcome your feedback. If you have any comments or suggestions, please let us know at marketing@rpharms.com.
Subscribe to this eNewsletter here
I Related Products
Medicines Complete BNF Pharmaceutical Press
BNF
Copyright © 2018 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved. Terms of use.
BNF for Children
Copyright © 2018 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved. Terms of use.
If you do not wish to receive such mailings in the future please click here to unsubscribe.
Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.